Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium tetravaccine tablets
- Development stage
- Unknown
- Lead developer
- Phathom Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Bifidobacterium tetravaccine tablets** are an oral live-microbial pharmaceutical product marketed as **Siliankang**. The product is a defined four-organism probiotic mixture containing *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. It is intended to restore intestinal microbial balance and support intestinal barrier function, with approved use in China for diarrhea, constipation, and functional dyspepsia associated with intestinal-flora disorders. Nanjing First Hospital is evaluating the product as an adjunct to vonoprazan-amoxicillin *Helicobacter pylori* eradication therapy in adults with metabolic syndrome, assessing effects on metabolic parameters and gut-microbiota composition.
- Brand names
- Siliankang
- Other names
- Bifidobacterium quadruple live tabletsBifidobacterium quadruple viable tabletsBifidobacterium tetragenous viable bacteria tabletsCombined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on bifidobacterium tetravaccine tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium tetravaccine tablets.